**TITLE**

Utilization of non-invasive urine sampling with multiplex PCR to enhance cervical cancer

screening in developing countries: a cross-sectional diagnostic accuracy study

**AUTHORS**

Novia Syari Intan[1], Revata Utama[1,*], Dewi Wulandari[2], Reiva Wisdharilla[2], Shafira Mutia

Khanza[1], Muhammad Rifki Ramadhan[1], Indah Suci Widyahening[3], Neni Nurainy[4], Rini Mulia

Sari[5], Andrijono[6]

**AFFILIATIONS**

[1] Nusantics, PT. Riset Nusantara Genetika, Jakarta, Indonesia

[2] Department of Clinical Pathology, Faculty of Medicine, Universitas Indonesia, Jakarta,

Indonesia

[3] Department of Community Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta,

Indonesia

[4] Translational Development of Life Science Product Division, PT Bio Farma, Bandung,

Indonesia

[5] Surveillance and Clinical Research Division, PT Bio Farma, Bandung, Indonesia

[6] Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Indonesia,

Jakarta, Indonesia

**CORRESPONDING AUTHOR**

*Revata Utama: revata@nusantics.com

**ABSTRACT**

**Background**

More than half of the predicted cervical cancer deaths are expected to be prevented with

improved screening and management strategies. However, the conventional cervical

screening procedure is considered as uncomfortable and embarrassing for most women in

developing countries, such as Indonesia, leading to a low participation rate of screening. In

response, we assessed the performance of the newly developed hrHPV ReadyMix qPCR Kit to

detect high-risk human papillomavirus (HPV) in urine samples and conduct simultaneous

genotyping of HPV16, HPV18, and HPV52.

**Methods**

We enrolled women aged 20-50 years from three cities in Indonesia, specifically Jakarta,

Bandung, and Semarang. Participants were instructed to provide self-collected first-void urine

samples, followed by a physician-assisted cervical swab sample collection. Nucleic acids were

then extracted and tested for HPV with Roche cobas® 6800 HPV and hrHPV ReadyMix qPCR

kit. Next generation-sequencing (NGS) was employed in cases of discrepant results. hrHPV

ReadyMix diagnostics accuracy were assessed against Roche cobas® 6800 HPV as a reference

test and the utility of urine samples as an alternative sampling method were compared to the

standard cervical swab samples.

**Results**

876 paired samples were analysed for HPV detection. The sensitivity of HPV detection in

cervical swabs using hrHPV ReadyMix qPCR Kit reached 96.55% and the specificity reached

99.87%. Despite having a tendency to produce higher Ct value in high-risk HPV detection,

urine samples produced a high sensitivity at 80.88% and a specificity of 100.00% when

compared to cervical swabs. Our developed method enables population-based high-risk HPV

analysis with 6.62% HPV prevalence based on cervical swabs and 6.28% HPV prevalence based

on urine samples. Urine samples, tested with the hrHPV ReadyMix qPCR Kit, exhibited

comparable HPV positivity rate to cervical swabs and similar genotyping capability of HPV16

and HPV18 as the Roche cobas® 6800 HPV system.

**Conclusions**

We demonstrated that self-collected urine samples can be an alternative specimen to detect

HPV infection with a diagnostic accuracy of 98.48%. This study highlights the potential of the

hrHPV ReadyMix qPCR Kit in improving cervical cancer screening and provides valuable

insights for future interventions.

**KEYWORDS**

Cervical cancer screening, high-risk human papillomavirus, HPV, HPV-DNA test, HPV

molecular test, in vitro diagnosis, urine specimens, polymerase chain reaction, qPCR, self-

collected specimen.

**BACKGROUND**

Cervical cancer is the fourth most prevalent type of cancer among women, with

approximately 604,127 cases and 341,831 fatalities worldwide in 2020.[1] The distribution of

cervical cancer cases varies across the globe, with developing countries accounting for 85%

of the mortality[2]. In Indonesia, it is estimated that there are approximately 36,633 cases and

21,003 deaths related to cervical cancer per year.[3] However, the disease is preventable and

treatable if detected early. As over 99% of precancerous lesions (cervical dysplasia) and

cervical carcinomas are caused by high-risk HPV infection,[4] detection of high-risk HPV as the

etiologic factor of cervical cancer cases has emerged as a primary early-screening method due

to its greater sensitivity than the Pap test for detecting precancerous lesions of the cervix.[5,6]

It also offers the advantage of extended screening intervals from once every 3 years to once

every 5 years as well as eliminating the need for skilled cytopathologists to interpret the

results[4,5].

However, implementation of HPV-based diagnostics in emerging countries faces a multitude

of challenges, such as the high costs of screening tests, shortages of the appropriate

diagnostic kits, and a lower than 10% screening participation rate in such countries, such as

Myanmar and Indonesia.[7,8] To increase the low participation rates, a self-sampling approach

combining detection of HPV from urine samples with the utilization of the currently available

infrastructure of quantitative polymerase chain reaction (qPCR) instruments was developed

as an alternative to cervical swab-based HPV screening method. The use of urine samples

offers several advantages, such as more privacy and less embarrassment in the sample

collection process, reduced discomfort and pain, as well as ease of use. Furthermore, previous

studies have shown that urine samples have a promising accuracy for HPV detection.[9-11] To

address those needs, the hrHPV ReadyMix qPCR Kit (ReadyMix) has been developed to detect

14 high-risk HPV types with the capability to genotype HPV52, HPV16, and HPV18 in both

cervical swabs and urine samples. HPV16 and HPV18 contribute to about 70% of all cervical

cancer cases. Alongside HPV52, they constituted the highest prevalence in Southeast Asia

countries.[4,12] Our study aimed to evaluate the performance of HPV detection in urine samples

as compared to standard cervical swabs using the ReadyMix, which was assessed for

performance against the Roche cobas® 6800 HPV system. The insights gained from this study

will contribute to the effort to achieve effective screening measures, not only in Indonesia

but also in other countries with similar settings, thus reducing the burden of the disease.

## MATERIALS AND METHODS

### Study Design and Population

This cross-sectional diagnostic test accuracy study was conducted based on HPV detection results from a study population comprising sexually active women aged 20 to 50 years residing in three major Indonesian cities: Jakarta, Bandung, and Semarang. The study focused on women who sought healthcare services for general medical check-ups, Pap smears, or visual inspection with acetic acid (VIA) test and willingly agreed to take part in the study. The subjects were asked to provide urine and cervical swab samples. Pregnant women, those currently menstruating, and individuals who had already received the HPV vaccine were excluded from the study. This recruitment was conducted between August 2022 and January 2023.

### Specimen Collection

The participants were first instructed to collect their first-void urine, collected at any time of the day, in a urine container. The cervical swab was then taken with a physician's assistance using a cervical brush and preserved in PreservCyt ® Solution (Hologic, Belgium). Both samples were kept at a temperature between 2-8°C and sent to the Clinical Pathology Department laboratory at the Cipto Mangunkusumo National Hospital for further analysis.

### DNA Extraction

The DNA was extracted from both urine and cervical swab samples using Zybio Nucleic Acid Extraction Kit (Zybio Inc., China) as per the manufacturer's instructions for ReadyMix. The integrity of the extracted DNA was assessed by detecting the β-globin gene, later in the qPCR

stage. The samples were simultaneously run in cobas®6800 HPV (Roche, Switzerland) where

extraction and amplification are integrated in automatic system.

**HPV qPCR and Genotyping Protocol**

The purified DNA was subjected to qPCR assays using ReadyMix performed in the CFX96™

System (Bio-Rad Lab, CA, USA) and using cobas® 6800 HPV (Roche, Switzerland) (cobas)

directly in the system. ReadyMix was developed by Nusantics and commercialized under the

name of PathoScan (Nusantics, Indonesia) and CerviScan (PT Biofarma, Indonesia). hrHPV

ReadyMix qPCR Kit targets the E6-E7 region to identify 14 high-risk HPV types while

concurrently differentiating between HPV16, HPV18, and HPV52. Other HPV types targeted

include HPV 31, 33, 35, 39, 45, 51, 56, 58, 59, 66, and 68, collectively detected in one

fluorescence channel. Both tests detect human β-globin gene as an internal control (IC) to

monitor the success of the extraction and qPCR procedure. cobas assay was performed

according to the manufacturer's instructions. ReadyMix reagent was pre-mixed in a single

tube and thus can be directly aliquoted to qPCR well in a volume of 15 μL for a 20 μL qPCR

reaction. This kit was then also used as per manufacturer recommendation, with PCR thermal

cycles consisting of 95°C initial denaturation for 2 minutes and 45 cycles of 1-second

denaturation at 95°C and 10 seconds annealing/extension at 60°C. The cutoff Ct value for a

sample to be considered positive is 40.

In samples that show discordant results between the two testing methods or between

different sample types, the presence of HPV DNA is confirmed using the amplicon sequencing

method utilizing NGS technology. DNA libraries were amplified by PCR, prepared using

Nextera XT index kit v2 (Illumina, CA, USA), and purified using AmPure XP beads (Beckman-

Coulter, CA, USA). Paired-end (2x150 bp) sequencing was performed using the Illumina Miseq

Micro v2 reagent kit (Illumina, CA, USA) on the MiSeq platform. The sequencing primers used

have been previously validated through alignment between the sequencing results of

synthetic genes and their corresponding references. Reads were demultiplexed based on

their index, resulting in a pair of forward and reverse fastq file for each sample. The

downstream data analysis was performed using QIIME2 platform.[13] Primer sequences were

trimmed and reads were filtered based on their length using cutadapt,[14] with a cutoff length

of 20. Forward and reverse reads were merged using vsearch,[15] allowing a maximum of 5

mismatches. In this step, a minimum merged read length of 30 for E6-E7 was enforced.

Merged reads were quality-filtered based on their Q score with a cutoff value of 30 prior to

dereplication. Reads were clustered *de novo* to produce operational taxonomic units with

99% similarity. Chimera sequences were filtered out using vsearch utility uchime-denovo. The

resulting sequences were classified into either of HPV types by mapping them to HPV

reference sequences that are obtained from Papillomavirus Episteme (PaVE)

(https://pave.niaid.nih.gov/). The mapping was performed using BLASTn with a minimum of

90% identity and a minimum word size of 20. [16]

**Statistical analysis**

The data were assessed for normality using the Shapiro-Wilk test. Categorical variables were

presented as percentages. For measures of central tendency, the mean ± standard deviation

(SD) was applied to normally distributed data, while the median (interquartile range; IQR) was

employed for non-normally distributed data. The study calculated the sensitivity, specificity,

positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy to

evaluate the diagnostic performance. Cohen's Kappa coefficient (**κ**) was used to determine

concordance between compared tests or samples.[17] The Wilcoxon matched-pairs signed rank

test was performed to compare qPCR Ct values between urine and cervical swabs. All

statistical analyses were executed using GraphPad statistical software version 10.0.2

(GraphPad San Diego, CA, USA).

**RESULTS**

**hrHPV ReadyMix qPCR Kit demonstrates high sensitivity and specificity in the detection of**

**high-risk HPV**

A total of 876 subjects from three sampling sites were included in this study. The mean age

of the subjects was 37.23±7.28 years. All subjects were tested for HPV by ReadyMix and

cobas. HPV detection in this study specifically refers to high-risk HPV detection. ReadyMix's

technical performance has been previously characterized based on linearity assay and limit of

detection (LoD) which yielded satisfactory results (Additional File 1: Supplementary Fig. S1,

S2). Among the 876 cervical swab and urine samples tested with cobas, there were 24 cervical

swab samples (2.74%) and 206 urine samples (23.52%) that yielded invalid results (Table 1).

On the other hand, ReadyMix produced a smaller number of invalid results, with only 2

cervical swab samples (0.23%) and 19 urine samples (2.17%) being invalid (Table 1).

Table 1. Summary of Test Participation and Validity in Study Subjects

| Results | ReadyMix | | cobas | |
|---|---|---|---|---|
| | Cervical Swab | Urine | Cervical Swab | Urine |
| Total subjects | 876 | 876 | 876 | 876 |
| Subject with complete test result | 874 | 857 | 852 | 670 |

| | | | | |
|---|---|---|---|---|
| Invalid | 2 | 19 | 24 | 206 |
| Invalid Rate | 0.23% | 2.17% | 2.74% | 23.52% |

188 We first sought to determine the diagnostic performance of ReadyMix in HPV detection using

189 the cervical swab as a standard method. The accuracy was excellent with a sensitivity of

190 96.15% (95% CI: 87.02-99.32%) and a specificity of 99.13% (95% CI: 98.2-99.58) (Table 2).

192 Table 2. HPV detection in the cervical swab using ReadyMix versus cobas

| Cervical Swab ReadyMix | Cervical Swab cobas | | | k-coefficient |
|---|---|---|---|---|
| | Positive | Negative | Total | |
| Positive | 50 | 7 | 57 | |
| Negative | 2 | 793 | 795 | 0.91 |
| Total | 52 | 800 | 852 | |
| Effect size | Value (%) | 95% CI (%) | | |
| Sensitivity | 96.15 | 87.02 - 99.32 | | |
| Specificity | 99.13 | 98.2 - 99.58 | | |
| Positive Predictive Value | 87.72 | 76.75 - 93.92 | | |
| Negative Predictive Value | 99.75 | 99.09 - 99.96 | | |
| Accuracy | 98.94 | 98.00 - 99.44 | | |

Upon observing samples with discordant results, we found that 6 out of 7 false-positives

results were confirmed true-positives by the NGS results (Additional File 1: Supplementary

Table S1). To obtain a clearer performance report of this assay, we then incorporate NGS data,

which resulted in 96.55% (95% CI: 88.27-99.39%) sensitivity and 99.87% (95% CI: 99.29-

99.99%) specificity (Table 3). Cohen's Kappa analysis (0.97) indicated an almost perfect

agreement between the compared methods.

Table 3. HPV detection in the cervical swab using ReadyMix versus cobas and NGS

| Cervical Swab ReadyMix | Cervical Swab cobas & NGS | | | k-coefficient |
|---|---|---|---|---|
| | Positive | Negative | Total | |
| Positive | 56 | 1 | 57 | |
| Negative | 2 | 793 | 795 | 0.97 |
| Total | 58 | 794 | 852 | |
| Effect size | Value (%) | 95% CI (%) | | |
| Sensitivity | 96.55 | 88.27 - 99.39 | | |
| Specificity | 99.87 | 99.29 - 99.99 | | |
| Positive Predictive Value | 98.25 | 90.71 - 99.91 | | |
| Negative Predictive Value | 99.75 | 99.09 - 99.96 | | |
| Accuracy | 99.65 | 98.97 - 99.90 | | |

**Urine samples exhibit an excellent agreement with cervical swabs in HPV detection**

To validate the use of urine sample for HPV detection, we compared its performance with a

well-established cervical swab sample. The NGS-corrected data were used to analyse the

ReadyMix's performance. The NGS results were attached in supplementary data (Additional

File 1: Supplementary Table S1; Supplementary Fig.S3). We found an almost perfect

agreement (**κ**: 0.89) between cervical swabs and urine with a sensitivity of 80.88% (95% CI:

69.99-88.47%) and 100% (95% CI: 99.51-100%) specificity (Table 4). This result demonstrates

enhanced accuracy in urine HPV detection on ReadyMix as compared to cobas (Additional File

1: Supplementary Table S2).

Table 4. HPV detection using ReadyMix in urine samples versus cervical swabs and NGS

| Urine ReadyMix | Cervical Swab ReadyMix & NGS | | | k-coefficient |
|---|---|---|---|---|
| | Positive | Negative | Total | |
| Positive | 55 | 0 | 55 | 0.89 |
| Negative | 13 | 787 | 800 | |
| Total | 68 | 787 | 855 | |
| Effect size | Value (%) | 95% CI (%) | | |
| Sensitivity | 80.88 | 69.99 - 88.47 | | |
| Specificity | 100.00 | 99.51 - 100 | | |
| Positive Predictive Value | 100.00 | 93.47 - 100 | | |
| Negative Predictive Value | 98.38 | 97.24 - 99.05 | | |
| Accuracy | 98.48 | 97.42 - 99.11 | | |

**Urine samples show a high sensitivity across low, moderate, and high cervical swab Ct value**

**group**

Upon analyzing the HPV's Ct values of paired cervical swab and urine samples, a significant

difference was observed between the two samples based on Wilcoxon matched-pairs signed

rank test (p-value <0.0001) (Fig. 1A). The cervical swabs exhibited a lower median HPV's Ct

value (31.89 (8.41)) as compared to urine samples (35.69 (3.85)), resulting in 3.80 of median

difference. The Ct value of IC detection also showed a similar pattern whereby cervical swabs

produced a lower median (26.685 (3.82)) as compared to urine samples (30.69 (3.18)) (Fig.

1B).

The HPV's Ct value median differences of the two samples follow a pattern whereby the

difference tends to be lower as the Ct values get higher. The low Ct group (Ct<30) of cervical

swab samples had median Ct value of 26.08 (3.51) with the corresponding urine samples

having a median Ct value of 34.11 (6.24) (Fig. 1C). The medium Ct group (Ct 30-35) had a

median Ct value of 31.63 (1.53) in cervical swabs while the corresponding urine samples have

a median Ct value of 36.26 (3.36) (Fig. 1C). The high Ct group (Ct>35), had cervical swab's

median Ct value of 36.76 (2.66) with the paired urine samples having a median of 36.39 (3.04)

(Fig. 1C). Thus, the median difference between urine and cervical swabs for low, medium, and

high Ct values were 8.03, 4.63, and 0.37, respectively. Despite the wider median gap at a

lower Ct value and a tendency to produce higher Ct, the sensitivity of urine samples is

maintained at a high level across all Ct groups, ranging from 80.88% positive percentage

agreement when considering all samples to 99.44% positive percentage agreement when

calculating for samples with Ct < 30 (Fig. 1D).

Figure 1. The Ct value of HPV detection in cervical swabs and urine samples was significantly different

(Wilcoxon matched-pairs signed rank test, p-value: <0.0001) with cervical swabs having a tendency to

produce a lower Ct value (A). This finding was supported by a similar pattern of the Ct value of IC

detection (B). However, the Ct value differences between cervical swabs and urine samples decrease

as the sample's Ct value increases (C), and the sensitivity of HPV detection in urine samples is

maintained at a high level across all Ct values.

**hrHPV ReadyMix qPCR Kit and cobas® 6800 HPV produced a comparable HPV prevalence**

**pattern across different age groups and locations**

A total of 876 subjects participated in this study consisting of 157 subjects within the age

group 20-29 (17.92%), 346 subjects within the age group 30-39 (39.50%), and 373 subjects

within the age group 40-50 (42.58%). As many as 385 subjects were from Jakarta (43.95%),

355 subjects from Bandung (40.53%), and 136 subjects from Semarang (15.53%) (Additional

File1: Supplementary Table S3).

Figure 2. ReadyMix identified a higher HPV prevalence, as supported by NGS results, indicating

increased sensitivity (A); This result slightly affected the prevalence distribution across different age

groups, where ReadyMix found a higher prevalence in the age group 40-50 compared to 30-39, while

cobas found the opposite (B). However, the two tests showed a similar trend, especially in discovering

the age group 20-29 to have the lowest prevalence among all groups. On the other hand, the

prevalence distributions based on locations observed by ReadyMix and cobas were less affected,

resulting in a similar pattern in both cervical swabs and urine samples (C).

The HPV prevalence of the study population was slightly higher when tested by ReadyMix as

compared to cobas (Fig. 2A). ReadyMix showed an HPV prevalence of 6.62% and 6.28%, based

on cervical swabs and urine respectively, while cobas showed an HPV prevalence of 5.94%

and 5.82%, based on cervical swabs and urine respectively. As previously described, most of

the additional positive samples were proven to be true-positives by NGS, suggesting the

superior performance of the ReadyMix. However, we found a similar HPV prevalence shown

by the two tests across different age groups and different locations.

The 20-29 age group had the lowest HPV prevalence according to both tests based on cervical

swabs (ReadyMix: 3.82%; cobas: 4.46%) and urine (ReadyMix: 3.82%; cobas: 3.18%) (Fig. 2B).

ReadyMix indicated a marginally higher prevalence in the age group of 40-50 (Cervical swab:

7.24%, Urine: 7.51%) compared to the 30-39 group (Cervical swab: 7.23%, Urine: 6.07%).

Conversely, cobas showed a higher prevalence in the 30-39 group (Cervical swab: 6.65%,

Urine: 6.94%) compared to the 40-50 group (Cervical swab: 5.90%, Urine: 5.90%) (Fig. 2B).

This contrasting finding mostly result from several (5 cervical swabs and 5 urine) samples from

the 40-50 group that were tested negative by cobas but were found to be HPV-positive by

ReadyMix and confirmed by NGS (Additional File 1: Supplementary Table S1).

Comparing the prevalence across different locations, both tests show that Semarang had the

highest HPV prevalence based on cervical swab samples (ReadyMix: 8.89%; cobas: 7.35%),

followed by Bandung (ReadyMix: 6.48%; cobas: 5.92%), while Jakarta presented with the

lowest HPV prevalence (ReadyMix: 5.97%; cobas: 5.45%) (Fig. 2C). This similar pattern was

also observed in urine samples with Semarang's HPV prevalence of 9.56% and 8.09% by

ReadyMix and cobas respectively, followed by Bandung (ReadyMix: 6.20%; cobas: 5.63%)

while Jakarta continued to have the lowest prevalence among the three locations (ReadyMix:

5.19%; cobas: 5.19%).

**Similar HPV positive percentage proportion is observed in both urine samples and cervical**

**swabs**

Besides the similar HPV prevalence, the pattern of HPV proportion in urine samples was also

proportional to that of cervical swabs, with HPV Others having the highest proportion

(Cervical swab: 50.00%; Urine: 45.45%), followed by HPV52 (Cervical swab: 17.24%; Urine:

21.82%), HPV16 (Cervical swab: 15.52%; Urine: 10.91%), and HPV18 (Cervical swab: 5.17%;

Urine: 7.27%) (Fig.3A). There were also some coinfection cases, which occupied 12.07% and

14.55% of HPV infection cases detected in cervical swabs and urine samples respectively.

Most of them were HPV52-HPV Others combination (Cervical swab: 57%; Urine: 50%) (Fig.

3B). The proportions of HPV16-HPV Others, HPV18-HPV Others, and HPV16-HPV52-HPV

Others in cervical swabs are all equal at 14% while HPV16-HPV Others' proportion (38%) is

higher than HPV18-HPV Others (13%) in urine samples. The HPV16-HPV52-HPV Others case

detected as HPV16-HPV Others contributed to this difference. A subset of coinfection samples

was also confirmed by NGS (Additional File 1: Supplementary Table S1; Supplementary Fig.S3)

with HPV31, HPV33, HPV51, HPV56, and HPV58 found, confirming the HPV Others detection

by qPCR.

The pattern of HPV proportion across different age groups by urine and cervical swabs share

a considerable similarity (Figure 3C). According to cervical swab samples, HPV Others

dominated the HPV type detected, (age group 20-29: 50.00%, age group 30-39: 36%, and age

group 40-50: 62.96%). The urine sample also showed an almost identical pattern (age group

30-39: 42.86%; age group 40-50: 50%), except for age group 20-29 where HPV Others share

the same proportion as HPV52 and coinfection cases at 33%. In the age group of 30-39, HPV52

and HPV16 shared a similar proportion with 24.00% and 28.00% in cervical swabs,

respectively, and both have 19.05% proportions in urine samples. A small proportion of

HPV18 was detected in this group's urine samples (4.76%), while none was found in cervical

swabs. This presence of HPV genetic materials has been confirmed with NGS, indicating that

the detection of HPV18 was not a false-positive result. In the age group of 40-50, cervical

swabs and urine displayed similar proportions of HPV16 (Cervical swab: 7.41%; Urine: 7.14%)

and HPV18 (Cervical swab: 11.11%; Urine: 10.71%), while HPV52's proportion was higher in

urine samples (21.43%) compared to cervical swabs (11.11%). This minor variation could be

attributed to the samples with discordant results between cervical swabs and urine.

Figure 3. The HPV proportions of each HPV type/ group found in urine samples were comparable to

cervical swabs (A). Urine samples also enable coinfection case detection, resulting in a pattern similar

to cervical swabs (B). Generally, the HPV type/group proportions found in urine are similar to cervical

swabs, across different age groups. A minor difference, where an HPV18 case found in the urine

sample of the 30-39 group was confirmed by NGS (C). Except for the absence of coinfection cases in

urine samples from Jakarta, the similarity in the pattern of HPV proportions between urine and cervical

swabs was also observed in a location-based analysis (D).

Analyzing the HPV prevalence by location, HPV Others remained dominant, except in

Semarang, where it shared the same proportion with coinfection cases (33.33%) as

determined by cervical swab (Fig. 3D). Semarang, in fact, had the highest coinfection cases

proportion in the urine sample (38.46%) when compared across all locations (Jakarta: 0.00%; Bandung: 13.64%). HPV52 holds the second largest proportion in Jakarta, in both cervical swabs (26.09%) and urine (35.00%), meanwhile, in Semarang, its proportion is the same as HPV16 at 15.38% in urine or lower when using cervical swabs (HPV52: 8.33%; HPV16: 25.00%). Both cervical swabs and urine displayed some small HPV18 proportions in Jakarta (Cervical swabs: 8.7%; Urine: 10%) and Bandung (Cervical swab: 4.35%; Urine: 9.09%), while there were none detected in Semarang. A single coinfection case was found in Jakarta based on cervical swabs (4.35%), while none was detected in urine samples. In Bandung, cervical swabs and urine showed a similar HPV52 proportion (Cervical swabs: 13.04%; Urine: 13.64%) while the HPV16 proportion is higher in the cervical swabs (13.04%) than in urine (9.09%).

**HPV16 and HPV18 genotyping results by hrHPV ReadyMix qPCR Kit is proportional to cobas® 6800 HPV**

To further validate the performance of ReadyMix, we compared the genotyping of HPV16 and HPV18 capability to cobas. The HPV16 proportion out of the positive HPV samples was found to be higher in cervical swabs (ReadyMix: 16.67%; cobas: 19.30%) as compared to urine samples (ReadyMix: 14.29%; cobas: 13.21%) (Fig. 4A, Additional File 1: Supplementary Table S4). The distribution of HPV16 across different age groups is consistent among all samples tested by ReadyMix and cobas with the highest prevalence observed in the age group of 30-39 (Cervical swab ReadyMix: 27.59%, cobas: 32.00%; Urine ReadyMix: 25.00%, cobas: 24.00%), followed by the 40-50 age group (Cervical swab ReadyMix: 10.34%, cobas: 12.00%; Urine ReadyMix: 9.68%, cobas: 4.35%) while no HPV16 found in the age group of 20-29 (Fig. 4B, Additional File 1: Supplementary Table S4).

When looking at HPV16 prevalence from the perspective of location origins, cobas detected

a higher proportion of HPV16 (46.15%) in cervical swabs samples when compared to results

detected by ReadyMix (29.41%) in Semarang (Fig. 4C). The total number of HPV-positive

samples detected with cobas were smaller when compared to ReadyMix (ReadyMix: 17 HPV-

positives; cobas: 13 HPV-positives) while the HPV16-positive samples detected with both

ReadyMix and cobas were similar (ReadyMix: 5 HPV16-positives; cobas: 6 HPV16-positives),

resulting in the difference in HPV16 prevalence. On the other hand, the urine samples

exhibited a more consistent results with 27.78% and 25.00% of HPV16 proportion when

tested with ReadyMix and cobas respectively. Cervical swab samples tested with ReadyMix

gave similar proportions of HPV16 in Jakarta (12.50%) and Bandung (12.00%) while a slightly

lower HPV16 proportion in Jakarta was obtained when tested using cobas (Jakarta: 9.52%;

Bandung: 13.04%). On the other hand, Bandung had a slightly lower HPV16 proportion as

compared to Jakarta when urine samples were tested with ReadyMix (Jakarta: 10.00%;

Bandung: 8.00%) and cobas (Jakarta: 10.00%; Bandung: 9.52%).

As for HPV18 prevalence, both tests showed a higher prevalence in urine samples (ReadyMix:

7.94%; cobas: 9.43%) when compared to cervical swab samples (ReadyMix: 6.06%; cobas:

7.02%) (Fig. 4D). The HPV18 proportion out of the positive HPV samples, in general, was

increased with increasing age group, except for the age group 30-39 where no samples tested

HPV18 positive (Fig. 4E). The age group of 40-50 had the highest HPV18 positive proportion

of 10.34% (ReadyMix) and 16.00% (cobas) on the cervical swab samples and 12.90%

(ReadyMix) and 13.04% (cobas) on the urine samples. There were no samples with HPV18

tested positive in the 20-29 group.

Location-based HPV positive proportion analysis indicated an agreement between the two

tests on the slightly higher HPV18 proportion in Jakarta (ReadyMix: 8.33%; cobas: 9.52%)

when compared to Bandung (ReadyMix: 8.00%; cobas: 8.70%) based on cervical swabs (Fig.

4F). On the other hand, urine samples showed a slightly higher HPV18 proportion found in

Bandung (ReadyMix: 12.00%; cobas: 14.29%) compared to Jakarta (ReadyMix: 10%; cobas:

10%). There were no samples in Semarang that tested HPV18 positive.

Figure 4. The pattern of HPV16 proportions among positive cases resulting from ReadyMix was similar

to cobas, where cervical swabs had a higher HPV16 proportion compared to urine (A). The similarity

was also observed when grouping the subjects into different age (B) and location categories (C). On

the other hand, the overall proportion of HPV18 found in urine samples was slightly higher than in

cervical swabs, as shown by both ReadyMix and cobas (D). The pattern was also observed when

analyzing based on age groups, except for cobas result in age group 40-50 where cervical swab has a

slightly higher HPV18 proportion (E). The HPV18 proportion across different locations, as detected by

ReadyMix and cobas, remained consistent, even in the presence of a minor pattern discrepancy

between cervical swabs and urine samples.

**DISCUSSION**

Our study demonstrates the good performance of the ReadyMix Kit in detecting HPV using

both standard cervical swab samples and urine samples, achieving a diagnostic accuracy of

99.65% and 98.48% respectively. These final results were also validated by NGS in which the

dispute samples were sequenced to confirm the presence of HPV genetic materials. We also

validated that the prevalence data of the high-risk HPV using urine samples are similar to

those of the cervical swab samples, indicating ReadyMix Kit's reliability in cervical cancer

screening.

The convenience of using urine as a sample for HPV detection has garnered interest as an

alternative to the conventional cervical swabbing method. The cervical examination is

frequently seen as an uncomfortable and embarrassing procedure, particularly among

women in emerging countries, restraining them from getting screened.[18,19] Nishimura et al.

(2021) have indicated that self-sampling is more acceptable as it protects privacy and reduces

anxiety.[20] Furthermore, Zhao et al. (2022) noted that women showed higher confidence in

correctly collecting urine samples rather than cervical samples.[7] Besides, the usage of self-

collected urine sample diminishes the need of skilled personnel and special supporting

equipment required for cervical swab sample collection.

Urine samples have been reported to show a promising performance compared to

conventional cervical swab samples for the detection of HPV.[9-11] Utilizing first-void urine is

crucial to acquire a greater quantity of exfoliated cells, which are likely to have a higher

concentration of HPV DNA.[9] In this study, we opted to collect first-void urine at any time of

the day for participants' convenience as there was no disparity in HPV DNA concentrations

between morning and subsequent urine samples as long as they were obtained within the

first-void phase.[21] A comprehensive analysis of multiple studies revealed that the combined

sensitivity of high-risk HPV detection in urine samples was 77%, with a specificity of 88%,

when compared to cervical samples.[9] We observed a higher sensitivity and specificity at

80.88% and 100%, respectively when tested using ReadyMix. The increased value was most

likely influenced by NGS confirmation, which verifies initially false-positive results to be true

positives. Additionally, ReadyMix exhibited lower rates of invalid results in urine samples

compared to cobas. These results highlight the potential of HPV detection in urine by

ReadyMix as a reliable screening method.

ReadyMix's good performance can also be shown in its similar HPV16 and HPV18 genotyping

results with cobas. This confirms the proficiency of ReadyMix in accurately determining the

HPV16 and HPV18-positive cases, providing clinicians with valuable information to guide

subsequent measures. The guideline suggests an additional evaluation such as colposcopy to

be performed in HPV16 and HPV18-positive patients, even when cytology results are

negative.[22] HPV52 genotyping as an additional genotyping capability of ReadyMix also helps

in covering the HPV type with the highest proportion among high-risk HPV detected in

Indonesia.[23] Our study found a higher proportion of HPV52 compared to HPV16 and HPV18

in both cervical swabs (HPV52: 17.24%; HPV16: 15.52%; HPV18: 5.17%) and urine (HPV52:

21.82%; HPV16: 10.91%; HPV18: 7.27%). The result was in line with a previous study where

HPV52, HPV16, and HPV18 comprised 23.2%, 18.0%, and 16.1% of the high-risk HPV-positive

cases in Indonesia.[23] Despite the 15-year gap, our study's findings continue to emphasize the

necessity of a vaccine covering the HPV52 type, in addition to HPV16 and HPV18, for the

Indonesian population.

The screening data by ReadyMix shows an HPV prevalence of 6.28-6.62%, slightly higher than

a previous study conducted in Indonesia with a total HPV prevalence of 5.2%, with high-risk

HPV contributing to 4.4% prevalence.[24] However, the prevalence is still lower than the

worldwide prevalence of high-risk HPV infection which is 10.4%.[25] Unlike most studies where

the HPV prevalence decreases with increasing age,[26] we found a lower HPV prevalence in the

lowest age group of 20-29 (Cervical swab: 3.82%; Urine: 3.82%) as compared to age group 30-

39 (Cervical swab: 7.23%; Urine: 6.07%) and age group 40-50 (Cervical swab: 7.24%; Urine:

7.51%). Vet et al. (2008) also observed that there was no decline in HPV prevalence in the

subjects of the older age group from Jakarta and Tasikmalaya.[23] Additionally, the increasing

prevalence in the older age groups was also found by Yang et al. (2020) in China, resulting in

the highest overall HPV prevalence held by age group ≥50 (10.53%), followed by 30-49

(8.29%), and the lowest held by age group <30 (7.30%).[27] Several factors that may account for

this phenomenon include a lower number of representatives in the young age group caused

by the randomized subject screening methodology of this study as well as potentially reduced

immunological functions of the older group, making them more susceptible to persistent HPV

infection.[27] Based on these data, we suggest an increased effort in the diagnosis of HPV

infection in older women as they have a higher risk of cervical cancer progression and lower

protection derived from vaccination[28].

We found HPV prevalence to be the highest in Semarang (Cervical swab: 8.82%; Urine:

9.56%), followed by Bandung (Cervical swab: 6.48%; Urine: 6.20%), and lastly Jakarta (Cervical

swab 5.97%; Urine: 5.19%). Here we can see that Jakarta, the biggest metropolitan city, had

the lowest HPV prevalence as compared to Semarang, a metropolitan city with a larger rural

area. Bandung, positioned with a metropolitan rating between the two cities,[29] also exhibits

a prevalence value that falls between the prevalence of the two aforementioned cities.

Despite many lifestyle factors influencing HPV prevalence in a community,[27] Sabeena et al.

(2017) discovered that the infection rate in rural women is higher than in those who lived in

urban areas due to lower access to cancer screening and oncology care.[30] This is a continuing

problem for emerging countries due to the inequality of access to healthcare services.

Chaturvedi et al. (2011) found a high proportion of HPV coinfection cases, reaching 43.2%

among 2478 HPV-positive women in Costa Rica.[31] The study suggested that multiple α9 types

(HPV16, 31, 33, 35, 52, and 58) infections significantly increased the risk of cervical squamous

intraepithelial neoplasia (CIN2+) and high-grade squamous intraepithelial lesions (HSIL)

compared to a single infection even though there was little evidence of any synergistic effect.

In our study, some individuals tested positive for multiple HPV types coinfection with a

mixture of HPV16-HPV Others, HPV18-HPV Others, HPV52-HPV Others, and HPV16-HPV52-

HPV Others. NGS results also revealed several samples in which multiple HPV Others types

were detected (Additional File 1: Supplementary Table 1). Additionally, we found a

combination of α9 types within a subset of samples we analyzed using NGS, particularly a

combination of HPV16, 52, 31, 33, and HPV58. This result indicated the importance of HPV

genotyping as a component of cervical cancer screening.

Our study to evaluate the usage of urine samples for cervical cancer screening using the hrHPV

ReadyMix Kit has several strengths. In addition to having a high number of participants across

multiple age groups, we also enrolled subjects from three major cities with varying

metropolitan ratings and likely different lifestyles.[29] This is particularly important to ensure

that the HPV detection method through urine samples is applicable to the Indonesian

population. Our study design also ensured that the paired urine samples and cervical swabs

were collected on the same day to reduce the variability of the result that might arise from

different sampling times. Additionally, urine samples were verified to be collected before the

cervical swab to reduce bias from additional cell debris that might come from the swabbing

procedure. We also implemented NGS to confirm the potential false-positive qPCR results to

check the presence of HPV in both cervical swabs and urine samples, which resulted in the

confirmation of HPV infection that was not detected by cobas. However, the main weakness

of our study is that we did not perform any cervical visual inspection to confirm the subject's

disease status and its relevance to qPCR results. These limitations should be overcome by

future studies to obtain a better perspective of high-risk HPV condition.

**CONCLUSIONS**

The use of hrHPV ReadyMix to detect HPV in urine sample resulted in 98.48% diagnostic

accuracy with 80.88% sensitivity and 100% specificity. Furthermore, the genotyping result

from urine samples were comparable to cervical swabs. Given the high diagnostic

performance, reduction in pain and anxiety during sample collection, and accurate

genotyping of the most prevalent HPV types, the implementation of urine sampling combined

with hrHPV ReadyMix qPCR Kit appears to be a promising method to overcome the challenges

of cervical cancer screening and aid in the facilitation of high-risk HPV surveillance as well as

vaccination strategies in many emerging countries, including Indonesia.

**ABBREVIATIONS**

CI:     Confidence Interval

HPV:   Human papillomavirus

IC:     Internal control

IQR:    Interquartile range

LoD:    Limit of detection

NGS:    Next-generation sequencing

NPV:    Negative Predictive Value

PPV:    Positive Predictive Value

qPCR:  quantitative polymerase chain reaction

SD:     standard deviation

VIA:    visual inspection with acetic acid

**DECLARATIONS**

**Ethics approval and consent to participate**

The collection of clinical samples, cervical swabs and urine samples, was approved by the

Health Research Ethics Committee of the Faculty of Medicine Universitas Indonesia Dr. Cipto

Mangunkusumo Hospital under the identifier No. KET- 674 / UN2.F1/ETIK/PPM.00.02/2022.

Informed consent was obtained from all participants and all methods were performed in

accordance with the Declaration of Helsinki and the approved Indonesian guidelines and

regulations for biomedical research.

**Consent for publication**

Not applicable.

**Availability of data and materials**

The datasets supporting the conclusions of this article are included within the article and its supplementary materials.

**Competing interests**

N.S.I., R.U., S.M.K., and M.R.R. are employees of Nusantics, PT Riset Nusantara Genetika. R.U. has financial holdings in Nusantics, PT Riset Nusantara Genetika. N.N. and R.M.S are employees at PT Bio Farma. The remaining authors declare that they have no conflict of interest.

**Funding**

This study was funded by PT Bio Farma in terms of subject recruitment, sample processing, and human resources. PT Bio Farma has a role in the study design, subject recruitment, and decision to submit the paper for publication. The development of the hrHPV ReadyMix kit and the NGS method were funded by Nusantics, PT Riset Nusantara Genetika, which also has a role in the study design, data collection, analysis, interpretation, report writing, and the decision to submit the paper for publication.

**Author's contribution**

R.U., D.W., A., and N.N. designed the study. R.U. designed the test kit. D.W., R.W., and R.M.S.

recruited the subjects. N.S.I., D.W., R.W., and R.M.S managed subjects' data. N.S.I., R.U., D.W.,

R.W., and I.S.W., analyzed and interpreted the data. N.S.I. and R.W. performed laboratory

experiments. S.M.K and M.R.R performed NGS experiments, analyzed, and interpreted NGS

data. N.S.I and R.U drafted the first version of the manuscript. N.N and A. provided valuable

suggestions to the manuscript. All authors read the manuscript, provided feedback, and

approved the submission.

**Acknowledgements**

We want to express our heartfelt thanks to all the dedicated healthcare personnel and

participants who made this research possible through their hard work and voluntary sample

contributions. Our appreciation extends to Cipto Mangunkusumo National Hospital for

providing essential facilities for sample analysis and to Nusantics, PT Riset Nusantara Genetika

for providing the ReadyMix kits and their valuable sequencing resources. We are grateful to

PT. Bio Farma for their financial support, which greatly assisted in our study. We would like

to acknowledge dr. Sri Harsi Teteki, dr. Indriastuti Soetomo, and Dicky Mahardika for their

vital role in managing the project. These contributions were crucial in our research, and we

are thankful for the collaboration and support that made this study successful.

**REFERENCES**

1   Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, Muñoz J, Bosch FX, de Sanjosé

S. Human Papillomavirus and Related Diseases in the World. Barcelona (ES): ICO/IARC

Information Centre on HPV and Cancer (HPV Information Centre); 2023 [updated 2023 Mar

10; cited 2023 May 4]. Available from: https://hpvcentre.net/statistics/reports/XWX.pdf

2  Zhang X, Zeng Q, Cai W, Ruan W. Trends of cervical cancer at global, regional, and national

level: data from the Global Burden of Disease study 2019. BMC Public Health. 2021

Dec;21(1):1–10.

3  Information Centre of HPV and Cancer. Human Papillomavirus and Related Cancers, Fact

Sheet 2023 [Internet]. Barcelona (ES): ICO/IARC Information Centre on HPV and Cancer (HPV

Information Centre); 2023 [updated 2023 March 10; cited 2023 May 4). Available from:

https://hpvcentre.net/statistics/reports/IDN_FS.pdf

4  Bedell SL, Goldstein LS, Goldstein AR, Goldstein AT. Cervical cancer screening: past, present,

and future. Sexual Medicine Reviews. 2020 Jan;8(1):28–37.

5  Fontham ET, Wolf AM, Church TR, Etzioni R, Flowers CR, Herzig A, Guerra CE, Oeffinger KC,

Shih YC–T, Walter LC, Kim JJ. Cervical cancer screening for individuals at average risk: 2020

guideline update from the American Cancer Society. CA: A Cancer Journal for Clinicians. 2020

Sep;70(5):321–46.

6  Liu SS, Chan KK, Wei TN, Tse KY, Ngu SF, Chu MM, Lau LS, Cheung AN, Ngan HY. Clinical

performance of the Roche Cobas 4800 HPV test for primary cervical cancer screening in a

Chinese population. PLoS One. 2022 Aug 5;17(8):e0272721.

7  Zhao S, Huang L, Basu P, Domingo EJ, Supakarapongkul W, Ling WY, Ocviyanti D, Rezhake R,

Qiao Y, Tay EH, Zhao F. Cervical cancer burden, status of implementation and challenges of

cervical cancer screening in Association of Southeast Asian Nations (ASEAN) countries.

Cancer Letters. 2022 Jan 28;525:22–32.

8    WHO. Cancer Country Profile 2020 [Internet]. Geneva (CH): WHO; 2020 [updated 2020; cited

2023  May  8].  Available  from:  https://cdn.who.int/media/docs/default-source/country-

profiles/cancer/idn-2020.pdf?sfvrsn=46ea6569_2&download=true

9    Pathak N, Dodds J, Zamora J, Khan K. Accuracy of urinary human papillomavirus testing for

presence of cervical HPV: systematic review and meta-analysis. BMJ. 2014 Sep 16;349:g5264

10   Choi YS, Jin H, Lee KE. Usefulness Analysis of Urine Samples for Early Screening of Human

Papilloma Virus Infection. Journal of Cancer Prevention. 2019 Dec;24(4):240.

11   Sargent A, Fletcher S, Bray K, Kitchener HC, Crosbie EJ. Cross-sectional study of HPV testing

in self-sampled urine and comparison with matched vaginal and cervical samples in women

attending colposcopy for the management of abnormal cervical screening. BMJ Open. 2019

Apr 1;9(4):e025388.

12   Peng RR, Li HM, Chang H, Li JH, Wang AL, Chen XS. Prevalence and genotype distribution of

cervical human papillomavirus infection among female sex workers in Asia: a systematic

literature review and meta-analysis. Sexual Health. 2011 Nov 23;9(2):113–9.

13   Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al. Reproducible,

interactive,  scalable  and  extensible  microbiome  data  science  using  QIIME  2.  Nature

biotechnology. 2019 Aug;37(8):852-7.

14   Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads.

EMBnet. journal. 2011 May 2;17(1):10-2.

15   Rognes T, Flouri T, Nichols B, Quince C, Mahé F. VSEARCH: a versatile open source tool for

metagenomics. PeerJ. 2016 Oct 18;4:e2584.

16   Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden TL. BLAST+:

architecture and applications. BMC bioinformatics. 2009 Dec;10:1-9.

17   Cohen J. A coefficient of agreement for nominal scales. Educational and psychological

measurement. 1960 Apr;20(1):37-46.

18   Robbers GML, Bennett LR, Spagnoletti BRM, Wilopo SA. Facilitators and barriers for the

delivery and uptake of cervical cancer screening in Indonesia: a scoping review. Global

Health Action. 2021 Jan 1;14(1):1979280.

19   Williams-Brennan L, Gastaldo D, Cole DC, Paszat L. Social determinants of health associated

with cervical cancer screening among women living in developing countries: a scoping

review. Archives of Gynecology and Obstetrics. 2012 Dec;286:1487–505.

20   Nishimura H, Yeh PT, Oguntade H, Kennedy CE, Narasimhan M. HPV self-sampling for

cervical cancer screening: a systematic review of values and preferences. BMJ Global Health.

2021 May 1;6(5):e003743.

21   Pattyn J, Van Keer S, Biesmans S, Ieven M, Vanderborght C, Beyers K, Vankerckhoven V,

Bruyndonckx R, Van Damme P, Vorsters A. Human papillomavirus detection in urine: Effect

of a first-void urine collection device and timing of collection. Journal of Virological Methods.

2019 Feb 1;264:23–30.

22   Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, Huh WK, Kim JJ, Moscicki

A, Nayar R, Saraiya M. 2019 ASCCP risk-based management consensus guidelines for

abnormal cervical cancer screening tests and cancer precursors. Journal of Lower Genital

Tract Disease. 2020 Apr;24(2):102.

23   Vet JN, De Boer MA, Van den Akker BEWM, Siregar B, Budiningsih S, Tyasmorowati D,

Cornain S, Peters AAW, Fleuren GJ. Prevalence of human papillomavirus in Indonesia: a

population-based study in three regions. British Journal of Cancer. 2008 Jul;99(1):214–8.

24   Handayani S, Dewi RM, Wibowo HA, Dany F, Kipuw NL, Adelina R, Adam K, Yunarto N, Idaiani

S, Kristanto AY. Cervical cancer risk factor: HPV infection among Indonesian urban women.

In: 4th International Symposium on Health Research (ISHR 2019) 2020 Feb 22 (pp. 452–5).

Atlantis Press

25 De Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide

prevalence and genotype distribution of cervical human papillomavirus DNA in women with

normal cytology: a meta-analysis. The Lancet Infectious Diseases. 2007 Jul 1;7(7):453–9.

26 Smith JS, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of infection with human

papillomavirus in females: a global review. Journal of Adolescent Health. 2008 Oct

1;43(4):S5–e1.

27 Yang J, Wang W, Wang Z, Wang Z, Wang Y, Wang J, Zhao W, Li D, Liu H, Hao M. Prevalence,

genotype distribution, and risk factors of cervical HPV infection in Yangqu, China: a

population-based survey of 10,086 women. Human Vaccines & Immunotherapeutics. 2020

Jul 2;16(7):1645–52.

28 Burger EA, Kim JJ, Sy S, Castle PE. Age of acquiring causal human papillomavirus (HPV)

infections: leveraging simulation models to explore the natural history of HPV-induced

cervical cancer. Clinical Infectious Diseases. 2017 Sep 15;65(6):893–9.

29 Demographia. Demographia world urban areas (built-up urban areas or urban

agglomerations); 2022 [updated 2023 Aug 31; cited 2023 Jul 17). Available from:

http://www.demographia.com/db-worldua.pdf.

30 Sabeena S, Bhat PV, Kamath V, Bhat SK, Nair S, Ravishankar N, Chandrabharani K, Arunkumar

G. Community-based prevalence of genital human papillomavirus (HPV) infection: a

systematic review and meta-analysis. Asian Pacific Journal of Cancer Prevention: APJCP.

2017;18(1):145.

31 Chaturvedi AK, Katki HA, Hildesheim A, Rodríguez AC, Quint W, Schiffman M, Van Doorn LJ,

Porras C, Wacholder S, Gonzalez P, Sherman ME. Human papillomavirus infection with

680 multiple types: pattern of coinfection and risk of cervical disease. The Journal of Infectious

681 Diseases. 2011 Apr 1;203(7):910-20.

683 **SUPPLEMENTARY INFORMATION**

684 Additional File 1.docx: **Supplementary Fig S1**. Linearity assay of ReadyMix in detecting 14

685 hrHPV types using HPV synthetic DNA as template ranging from 100 to 100,000 GE

686 copies/reaction. A) HPV16; B) HPV18; C) HPV52; D) HPV35; E) HPV31; F) HPV33; G) HPV39; H)

687 HPV45; I) HPV51; J) HPV56; K) HPV58; L) HPV59; M) HPV66; N) HPV68. This assay

688 demonstrated excellent efficiency with a range between 90-110% and $R^2$~1. **Supplementary**

689 **Fig S2**. Limit of Detection (LoD) of ReadyMix for each hrHPV target ranging from 10-28

690 copies/20 uL qPCR reaction. **Supplementary Table S1**. The results of NGS run to investigate

691 the presence of hrHPV in the samples based on E6-E7 amplicon sequencing. **Supplementary**

692 **Fig S3**. Stacked taxa bar plot showing the relative abundance of HPV type found in the sample

693 **Supplementary Table S2**. HPV detection using cobas in urine versus cervical swab and NGS.

694 **Supplementary Table S3**. Demographics of the study population. **Supplementary Table S4**.

695 HPV16 and HPV18 proportion within all HPV cases.